MANAGE OAB SYMPTOMS IN ELDERLY LTC RESIDENTS
Urinary incontinence (UI) is common among long term care (LTC) residents, with 75% of residents at least occasionally incontinent1
Urge urinary incontinence (UUI), a type of urinary incontinence, is a key symptom of overactive bladder (OAB).* However, only 1 out of 4 residents†
receive pharmacological treatment for their symptoms. Undiagnosed OAB may negatively impact residents in a nursing home.2-4
As many residents suffer from cognitive decline, they may have difficulty reporting OAB symptoms.5
Here’s what to look for:
Frequency Urinating 8+ times per day6
Urge urinary incontinence Involuntary leakage episodes (which may require use of absorbent products)7
Urgency episodes The sudden need to urinate2
CONSIDER TREATMENT WITH ESTABLISHED SAFETY AND TOLERABILITY FOR ELDERLY PATIENTS WITH OAB
*The 3 key symptoms of OAB are urgency, micturition frequency, and UUI/leakage.8 †
Based on an integrated claims database analysis of 159,785 LTC residents with OAB.3
INDICATION AND USAGE GEMTESA is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS GEMTESA is contraindicated in patients with known hypersensitivity to vibegron or any components of the product.
WARNINGS AND PRECAUTIONS Urinary Retention
Urinary retention has been reported in patients taking GEMTESA. The risk of urinary retention may be increased in patients with bladder outlet obstruction and also in patients taking muscarinic antagonist medications for the treatment of OAB. Monitor patients for signs and symptoms of urinary retention, particularly in patients with bladder outlet obstruction and patients taking muscarinic antagonist medications for the treatment of OAB. Discontinue GEMTESA in patients who develop urinary retention.
References: 1. Department of Health and Human Services (DHHS), Centers for Medicare & Medicaid Services (CMS). MDS 3.0 Frequency Report. Accessed January 29, 2021.
https://www.cms.gov/Research-Statistics-Data-and-Systems/Computer-Data-and-Systems/Minimum-Data-Set-3-0-Public-Reports 2. Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. American Urological Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction; 2019. Accessed July 20, 2021.
https://www.auanet.org/guidelines/ overactive-bladder-(oab)-guideline 3. Data on file. Urovant Sciences. 4. Lukacz ES, Sampselle C, Gray M, et al. A healthy bladder: a consensus statement. Int J Clin Pract. 2011;65(10):1026-1036. 5. Zimmerman S, Sloane PD, Reed D. Dementia prevalence and care in assisted living. Health Aff (Millwood). 2014;33(4):658- 666. doi:10.1377/hlthaff.2013.1255 6. Blaivas JG, Sandha J. Clinical evaluation of lower urinary tract symptoms. In: Raz S, Rodriguez LV, eds. Female Urology. 3rd ed. Elsevier; 2008:77-85. 7. Leung FW, Schnelle JF. Urinary and fecal incontinence in nursing home residents. Gastroenterol Clin North Am. 2008;37(3):697-707. doi:10.1016/
j.gtc.2008.06.005 8. Edmondson SD, Zhu C, Kar NF, et al. Discovery of vibegron: a potent and selective β3
adrenergic receptor agonist for the treatment
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
